Cambridge Healthtech Institute to Host Eighth International Discovery on Target

Oct. 8, 2010 - PRLog -- NEEDHAM, MASS. – Cambridge Healthtech Institute, a premier information provider for the life sciences industry, will host its Eighth International Discovery on Target meeting on November 2-4, 2010 in Boston, Massachusetts.

This internationally renowned event continues to grow and to present novel “hot” targets for the pharmaceutical industry.  Discovery on Target has expanded this year to include 8 conference tracks, and 5 short courses.  New additions to the event include the inaugural meetings on COPD and other chronic pulmonary diseases as well as on PI3K Pathways

Cambridge Healthtech Institute’s Discovery on Target assembles an impressive group of distinguished speakers who are looking forward to sharing their knowledge with the attendees.  Networking opportunities will be available through interactive sessions including roundtable breakouts, workshops and panel discussions.

Conference tracks include:
•   Targeting the PI3K Pathway (November 2-3)
•   HDAC Inhibitors (November 2-3)
•   GPCR-Based Drug Discovery (November 2-3)
•   Ion Channels as Therapeutic Targets (November 2-3)
•   Kinase Inhibitors (November 3-4)
•   New Ways to Tackle COPD and Other Chronic Pulmonary Diseases (November 3-4)
•   RNAi for Functional Screens (November 3-4)
•   Diabetes Drug Discovery (November 3-4)

Keynote presentations include: Ian Adcock, Ph.D., Professor, Respiratory Cell & Molecular Biology, Airways Disease Section, National Heart and Lung Institute and Faculty  of Medicine, Imperial College, London; Gregory J. Kaczorowski, Ph.D., President, CEO, Kanalis Consulting, L.L.C.; Adjunct Professor, Physiology and Pharmacology, New Jersey Medical School, Adjunct Professor, Physiology and Biophysics, Robert Wood Johnson Medical School; Laszlo Kiss, Ph.D., Cell Biology Team Lead, Merck Research Laboratories ; Spyro Mousses Ph.D., Vice President, Office of Innovation and Director, Center of BioIntelligence, Translational Genomics Research Institute; Jorge Plutzky, M.D., Director, The Vascular Disease Prevention Program, Cardiovascular Division, Brigham and Women’s Hospital and Associate Professor, Harvard Medical School; Thomas Sakmar, M.D., Professor, Molecular Biology and Biochemistry, Rockefeller University Edward Seto, Ph.D., Chairman, Department of Molecular Oncology, H. Lee Moffitt Cancer Center.

In addition, interactive breakout discussion groups will be held. Join a facilitated discussion group focused around scientific and technology related topics. These unique sessions allows conference participants to exchange ideas, experiences, and develop future collaborations around a focused topic.

Topics include:
•   The ‘under-class’ of GPCRs: Class C Receptors
•   Deploying GPCR Crystal Structures to Screening and Design: Opportunities and Challenges
•   Challenges of Generating Therapeutic Biologics to GPCRs
•   How Will We Discover Novel Therapies for Diabetes that are Safe and Efficacious?
•   Challenges in Pancreatic Regeneration-Approaches
•   Preclinical Development of Diabetes Compounds – Pitfalls to Avoid
•   And more

For more information about the conference, please visit http://www.discoveryontarget.com.

About Cambridge Healthtech Institute

Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.
Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business. www.chicorporate.com

For more information:
Olga Pavleyeva
Marketing Manager
Cambridge Healthtech Institute
(781) 972-5492
opavleyeva@healthtech.com

# # #

Since 1992, Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations.